A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
At the World Economic Forum (WEF), Deloitte's Nitin Mittal stressed that successful enterprise AI adoption hinges on building trust, fostering organizational readiness, and managing change. He ...
Gloved hands hold two square metal pieces. The piece on the left has a black square in its center. This simple electrochemical device captures carbon dioxide from simulated industrial exhaust thanks ...
Nearly two years after Google DeepMind released an updated AlphaFold3 geared at drug discovery, its biopharmaceuticals spin-off, Isomorphic Labs, announced an even more powerful ...
The unified JavaScript runtime standard is an idea whose time has come. Here’s an inside look at the movement for server-side JavaScript interoperability. The WinterCG community group was recently ...
Nearly two years after Google DeepMind released AlphaFold 3, an updated version of its system for predicting protein structure that is geared towards drug discovery, its biopharmaceuticals spin-off, ...
Artificial intelligence and quantum computing are no longer hypothetical; they are actively altering cybersecurity, extending attack surfaces, escalating dangers, and eroding existing defenses. We are ...
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Deep Origin, the computational drug discovery company replacing guesswork with prediction in small molecule drug development, today ...
Cybersecurity researchers have discovered a JScript-based command-and-control (C2) framework called PeckBirdy that has been put to use by China-aligned APT actors since 2023 to target multiple ...
In 2025, the Nobel Prize in Chemistry honored Susumu Kitagawa, Richard Robson, and Omar M. Yaghi for pioneering a new way to build materials from metal nodes and organic linkers. 1 These crystalline ...
Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results